13 research outputs found
Proposed Mode of Binding and Action of Positive Allosteric Modulators at Opioid Receptors
Available
crystal structures of opioid receptors provide a high-resolution
picture of ligand binding at the primary (āorthostericā)
site, that is, the site targeted by endogenous ligands. Recently,
positive allosteric modulators of opioid receptors have also been
discovered, but their modes of binding and action remain unknown.
Here, we use a metadynamics-based strategy to efficiently sample the
binding process of a recently discovered positive allosteric modulator
of the Ī“-opioid receptor, BMS-986187, in the presence of the
orthosteric agonist SNC-80, and with the receptor embedded in an explicit
lipidāwater environment. The dynamics of BMS-986187 were enhanced
by biasing the potential acting on the ligandāreceptor distance
and ligandāreceptor interaction contacts. Representative lowest-energy
structures from the reconstructed free-energy landscape revealed two
alternative ligand binding poses at an allosteric site delineated
by transmembrane (TM) helices TM1, TM2, and TM7, with some participation
of TM6. Mutations of amino acid residues at these proposed allosteric
sites were found to either affect the binding of BMS-986187 or its
ability to modulate the affinity and/or efficacy of SNC-80. Taken
together, these combined experimental and computational studies provide
the first atomic-level insight into the modulation of opioid receptor
binding and signaling by allosteric modulators
CXCR7/CXCR3 tail switch alters ubiquitination properties of the receptors.
<p>(<b>A</b>) Immunoprecipitation experiments were performed in cells expressing chimeric receptors consisting on CXCR7 with CXCR3 C-terminus (CXCR7-X3) or the reciprocal CXCR3 with CXCR7 C-terminus (CXCR3-X7). Detection of the immunoprecipitated CXCR7 and CXCR3 was done with the 11G8 and mAB160 antibodies, respectively. HA-Ub expression was confirmed blotting lysates using an anti-HA antibody and equal loading was controlled by detection of actin on the same blot. Molecular weight markers (kDa) are indicated on the sides of the blots. (<b>B</b>) Detection of total CXCR7 protein expression by ELISA in the same cells.</p
CXCR7 recycles to the cell surface after internalization.
<p>(<b>A</b>) HEK293T stably expressing CXCR7 were stimulated with 10<sup>ā8</sup> M CXCL11, CXCL12 or vehicle for 45 min or 3 h and fixed immediately. CXCR7 was detected using the specific 11G8 antibody and an Alexa-488-conjugated secondary antibody. Scale bar represents 10 Āµm. (<b>B</b>) HEK293T cells expressing CXCR7 (filled symbols) or CXCR3 (open symbols) were incubated with CXCL11 (10<sup>ā8</sup> M, squares), CXCL12 (10<sup>ā8</sup> M, triangles) or vehicle (circles) for the indicated times. Cell surface receptor levels were detected by ELISA using CXCR7- or CXCR3-specific antibodies (11G8 and mAB160, respectively). Results were normalized to basal surface protein levels, and data represent the mean Ā± SEM of 4 experiments each performed in triplicate. (<b>C</b>) ELISA was performed as in B in cells pre-incubated for 2 h with the <i>de novo</i> protein synthesis inhibitor cycloheximide (10 Āµg/ml). (<b>D</b>) ELISA performed as in C on intact HEK293/CXCR7 cells treated with vehicle or 1 ĀµM of bafilomycin A1 (Baf A1), 30 min prior to incubation with CXCL12. <b>(E) C-terminal Ser/Thr clusters determine receptor fate after internalization.</b> HEK293T cells were transiently transfected with CXCR7 wt (white bars) or with a chimeric receptor consisting of CXCR7 harboring the C-terminal sequence of CXCR3 (CXCR7-X3, filled bars). To assess the cell surface expression of the receptor, ELISA experiments were performed after 30 min or 3 hours of incubation with 10<sup>ā8</sup> M CXCL12. Data represent the mean Ā± SEM of 3 experiments each performed in triplicate. ***, p<0.001, **, p<0.01, and *, p<0.05 by one-way ANOVA and Bonferroni post test.</p
Real-time monitoring of receptor ubiquitination using BRET<sup>2</sup>.
<p>HEK293T cells were transfected with Ub-GFP<sup>2</sup> (white bars) or (G75A,G76A)-Ub-GFP<sup>2</sup> (filled bars) and (<b>A</b>) CXCR7-RLuc, CXCR7 ĪC-RLuc, or CXCR7 ST/A-Rluc, (<b>B</b>) CXCR4-RLuc, or (<b>C</b>) CXCR3-RLuc. BRET<sup>2</sup> was measured 30 min after stimulation with 10<sup>ā8</sup> M of CXCL12 (CXCL11 for CXCR3) by addition of coelenterazine 400a and immediate read out. Results are expressed in Net BRET normalized to basal as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0034192#s4" target="_blank">Materials and Methods</a>. Data represent the mean Ā± SEM of 3 experiments each performed in triplicate. **, p<0.01, and ***, p<0.001, by Student t test.</p
Ī²-arrestin2 recruitment to CXCR7 is dependent on C-terminal Ser/Thr residues.
<p>(<b>A</b>) CXCL11 or CXCL12-mediated Ī²-arrestin2 recruitment to CXCR7. HEK293T co-expressing RLuc-tagged CXCR7 and YFP-tagged Ī²-arrestin2 were stimulated with increasing concentrations of CXCL11 (open circles) or CXCL12 (filled circles) (<b>B</b>) HEK293T co-expressing RLuc-tagged CXCR7 and YFP-tagged Ī²-arrestin2 were incubated overnight with 25 ng/ml of PTX or for 30 min with the CXCR7-specific antibody 8F11 prior to the BRET measurement. (<b>C</b>) CXCL12-induced Ī²-arrestin2 recruitment to CXCR7 wt (filled circles), a truncated CXCR7 lacking the C-terminus (CXCR7 ĪC, filled triangles) or a mutant CXCR7 for which all the Ser and Thr residues were mutated to Ala (CXCR7 ST/A, open squares). HEK293T cells coexpressing <i>RLuc</i>-tagged CXCR7 mutants and YFP-tagged Ī²-arrestin2 were stimulated with increasing concentrations of CXCL12 prior to BRET measurements. Data represent the mean Ā± SEM of 4 experiments each performed in triplicate. Results are expressed in Net BRET as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0034192#s4" target="_blank">Materials and Methods</a>. ***, p<0.001 by one-way ANOVA and Bonferroni post test.</p
The C-terminus of CXCR7 is constitutively ubiquitinated.
<p><b>(A) CXCR7 gets deubiquitinated by CXCL12-stimulation.</b> HEK293T cells were transfected as indicated and processed for immunoprecipitation of the HA-Ub (See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0034192#s4" target="_blank">Materials and Methods</a>). (<b>A</b>) CXCR7 was stimulated with 10<sup>ā8</sup> M CXCL12 for 30 min, and removal of CXCL12 was performed by two washes of the cells and additional 30 min incubation with fresh chemokine-free media. Detection of the immunoprecipitated CXCR7 was done with the 11G8 antibody. HA-Ub expression was confirmed by blotting lysates using an anti-HA antibody and equal loading was controlled by detection of actin on the same blot. Molecular weight markers (kDa) are indicated on the right of the blot. (<b>B</b>) Detection of total CXCR7 protein expression by ELISA in the same cells.</p
Proposed model for regulation of CXCR7 trafficking.
<p>CXCR7 requires ubiquitination of the Lys residues of its C-tail in order to reach the cell surface. Receptor activation by CXCL12 and subsequent phosphorylation of the C-terminal Ser/Thr residues results in Ī²-arrestin recruitment by CXCR7 and receptor internalization in CCPs. In addition, Ī²-arrestin scaffolds the interaction of CXCR7 with an unknown de-ubiquitinating enzyme (DUB) responsible for receptor deubiquitination. After chemokine degradation in early endosomes and due to the transient interaction of CXCR7 with Ī²-arrestin, release of Ī²-arrestin (and DUB) from the endocytosed receptor results in a CXCR7 able to undergo ubiquitination by a specific E3 ligase (E3) and subsequent delivery of the recycled receptor to the cell surface.</p
(A) CXCR7 internalization depends on CCPs and is G protein-independent.
<p>HEK293T cells were transfected with wt CXCR7 (and Ī²-arrestin (319ā418) were indicated) and cell surface levels of the receptor after CXCL12 stimulation was detected by ELISA using the CXCR7-specific antibody 11G8. Incubation with 0.4 M Sucrose was done 30 min prior and during stimulation. PTX was incubated overnight at 25 ng/ml final concentration. <b>(B) Ī²-arrestin1/2 knock-down prevents CXCR7 internalization.</b> HEK293/CXCR7 cells transfected with control siRNAs (white bars) or pools targeting Ī²-arrestin1/2 (filled bars), were stimulated with CXCL12 (10<sup>ā8</sup> M) or vehicle for 45 min and receptor surface expression was determined. Knockdown of Ī²-arrestin1 and -2, 48 hrs after transfection, was assessed in western blot using an anti-Ī²āarrestin1/2 antibody (inset). Anti-STAT3 (mAb 79D7, Cell Signaling Technologies) was used as loading control. <b>(C) CXCR7 C-terminus is essential for receptor internalization.</b> HEK293T cells were transfected with wt CXCR7 (filled bars), CXCR7 ĪC (grey bars) or CXCR7 ST/A (white bars) and cell surface receptor levels were assessed as above. Data represent the mean Ā± SEM of at least 3 experiments each performed in triplicate. ***, p<0.001 by one-way ANOVA and Bonferroni post test.</p
Pharmacological and Physicochemical Properties Optimization for Dual-Target Dopamine D<sub>3</sub> (D<sub>3</sub>R) and Ī¼āOpioid (MOR) Receptor Ligands as Potentially Safer Analgesics
A new generation of dual-target Ī¼ opioid receptor
(MOR) agonist/dopamine
D3 receptor (D3R) antagonist/partial agonists
with optimized physicochemical properties was designed and synthesized.
Combining in vitro cell-based on-target/off-target affinity screening,
in silico computer-aided drug design, and BRET functional assays,
we identified new structural scaffolds that achieved high affinity
and agonist/antagonist potencies for MOR and D3R, respectively,
improving the dopamine receptor subtype selectivity (e.g., D3R over D2R) and significantly enhancing central nervous
system multiparameter optimization scores for predicted bloodābrain
barrier permeability. We identified the substituted trans-(2S,4R)-pyrrolidine and trans-phenylcyclopropyl amine as key dopaminergic moieties
and tethered these to different opioid scaffolds, derived from the
MOR agonists TRV130 (3) or loperamide (6). The lead compounds 46, 84, 114, and 121 have the potential of producing
analgesic effects through MOR partial agonism with reduced opioid-misuse
liability via D3R antagonism. Moreover, the peripherally
limited derivatives could have therapeutic indications for inflammation
and neuropathic pain
Pharmacological and Physicochemical Properties Optimization for Dual-Target Dopamine D<sub>3</sub> (D<sub>3</sub>R) and Ī¼āOpioid (MOR) Receptor Ligands as Potentially Safer Analgesics
A new generation of dual-target Ī¼ opioid receptor
(MOR) agonist/dopamine
D3 receptor (D3R) antagonist/partial agonists
with optimized physicochemical properties was designed and synthesized.
Combining in vitro cell-based on-target/off-target affinity screening,
in silico computer-aided drug design, and BRET functional assays,
we identified new structural scaffolds that achieved high affinity
and agonist/antagonist potencies for MOR and D3R, respectively,
improving the dopamine receptor subtype selectivity (e.g., D3R over D2R) and significantly enhancing central nervous
system multiparameter optimization scores for predicted bloodābrain
barrier permeability. We identified the substituted trans-(2S,4R)-pyrrolidine and trans-phenylcyclopropyl amine as key dopaminergic moieties
and tethered these to different opioid scaffolds, derived from the
MOR agonists TRV130 (3) or loperamide (6). The lead compounds 46, 84, 114, and 121 have the potential of producing
analgesic effects through MOR partial agonism with reduced opioid-misuse
liability via D3R antagonism. Moreover, the peripherally
limited derivatives could have therapeutic indications for inflammation
and neuropathic pain